David Schenkein, MD
Chief Executive Officer, Agios
David Schenkein, MD, is the chief executive officer of Agios and a member of the company’s board of directors. He has been a hematologist and medical oncologist for more than 20 years.
He currently serves as an adjunct attending physician in hematology at Tufts Medical Center. Prior to joining Agios, David was the senior vice president of clinical hematology/oncology at Genentech, where he was responsible for numerous successful oncology drug approvals and led the medical and scientific strategies for the BioOncology portfolio. While at Genentech, he also served as an adjunct clinical professor of medical oncology at Stanford University School of Medicine. Prior to joining Genentech, he served as the senior vice president of clinical research at Millennium Pharmaceuticals, a wholly-owned subsidiary of Takeda Pharmaceuticals, overseeing the clinical development and worldwide approval of Velcade®, a first-in-class cancer therapy now approved to treat multiple myeloma and non-Hodgkins lymphoma. He currently serves on the board of directors of bluebird bio and Denali Therapeutics.
David holds a BA in chemistry from Wesleyan University, in Connecticut, and an MD from the State University of New York Upstate Medical School.